

NEPEAN BLUE MOUNTAINS LOCAL HEALTH DISTRICT HUMAN RESEARCH ETHICS COMMITTEE
CERTIFICATE OF APPROVAL

Monday, 6 July 2020

A/Professor George Condous
O & G
Nepean Hospital

This letter constitutes ethical approval only. You must NOT commence this research project at ANY site until you have submitted a Site Specific Application to the RESEARCH GOVERNANCE OFFICER and received a separate authorisation from the Chief Executive or their delegate.

Dear A/Professor Condous,

HREC study reference: 2019/ETH13390

Study title: Diagnostic accuracy of transvaginal ultrasound, magnetic resonance imaging and positron emission tomography-computed tomography with 16 α -[18F]fluoro-17 β -estradiol for the diagnosis of rectosigmoid deep endometriosis

Your request to undertake the above protocol was considered by the NBMLHD Human Research Ethics Committee (HREC) at the following meetings;

- HREC Meeting 3/12/2019
- HREC Executive Meeting 11/2/2020
- HREC Executive Meeting 2/6/2020
- HREC Meeting 16/6/2020

On receipt of your response dated 20/1/2020, 19/2/2020, 27/2/2020, 28/5/2020 & 1/7/2020 to the concerns of the Committee dated 16/12/2019, 22/1/2020, 7/2/2020, 21/2/2020, 4/3/2020 & 26/6/2020 we are satisfied that your protocol meets the requirements of the National Statement on Ethical Conduct in Human Research (2007) and was APPROVED on the 6th July 2020 to be conducted as a multi-site study.

It is the Principal Investigator's responsibility to ensure that all researchers associated with this project are aware of the conditions of approval and which documents have been approved.

The Principle Researcher is required to note the following conditions of approval:

- The coordinating investigator will immediately report anything which might warrant review of ethical approval of the project in the specified format, including unforeseen events that might affect continued ethical acceptability of the project.

2019/ETH13390 – Cont'd

- The coordinating investigator will immediately report any protocol deviation / violation, together with details of the procedure put in place to ensure the deviation / violation does not recur.
- The Coordinating Investigator will provide to the HREC in the specified format proposed amendments to the protocol or conduct of the research which may affect the ethical acceptability of the project. Copies of all proposed changes when approved by the HREC must also be provided to the research governance officer.
- The HREC must be notified, giving reasons, if the project is discontinued at a site before the expected date of completion.
 - The Coordinating Chief Investigator must provide an annual report to the HREC and a final report at completion of the study, in the specified format. HREC approval is granted for a period of 5 years and ongoing approval is contingent upon annual report submission. Annual Reports for all studies should be submitted on the anniversary of the approval date of project. They will be processed and presented to the HREC at the next scheduled meeting. Annual / Final reports must be submitted via REGIS <https://regis.health.nsw.gov.au/>
- It should be noted that compliance with the ethical guidelines is entirely the responsibility of the investigators.
- The HREC has the discretion to adopt other appropriate mechanism for monitoring depending on the complexity, design and risk perceived, including:
 - Discussion of relevant aspects of the project with investigators at any time.
 - Random inspection of research sites, data or consent
 - Interview with research participants or other formats of feedback from them.
 - Request and review reports from independent agencies such as Data and Safety Monitoring Board.
- For clinical trials using implantable medical devices, the coordinating investigator will confirm to the HREC that a process has been established for tracking participants with consent for the lifetime of the device and will immediately report any device incidents to the Therapeutic Goods Administration (TGA).
- If your research project is an interventional trial please ensure you register your trial onto one of the clinical trial registries, for example. <http://www.anzctr.org.au/>
 - The storage of study data should be as per the GDA 17 Public Health Patient Records, Section 8.0 Research Management. For Clinical Trials data should be stored for 15 years from the date of publication or completion / termination of the study then destroy. For non-clinical trials study data should be stored for 5 years from the date of publication or completion / termination of the study then destroy. <https://www.records.nsw.gov.au/recordkeeping/rules/gdas/gda17>

The NBMLHD HREC has been accredited by the NSW Ministry of Health as a lead HREC to provide the single ethical and scientific review of proposals to conduct research within the NSW public health system. This lead HREC is constituted and operates in accordance with the National Health and Medical Research Council's *National Statement on Ethical Conduct in Human Research* and the *CPMP/ICH Note for Guidance on Good Clinical Practice for the review of multi-site research proposals*.

SPECIAL CONDITIONS:

- **CTN to be completed with the NBMLHD Research Governance Officer for the TGA.**
- **Please ensure this trial is registered with a clinical trial registry.**
- **External Entity Agreements executed for OMNI Gynaecological Care and Sydney Adventist Hospital.**
- **Research Data Management Plan to be submitted with Site Application for RGO review.**

2019/ETH13390 – Cont'd

Approved Documents:

Documents reviewed and approved at the meeting were:

| Document | Version | Date |
|--|---------|------------|
| HREA | 6 | 26/6/2020 |
| Protocol | 6 | 1/7/2020 |
| Radiation Safety Report | - | 4/10/2019 |
| De-identified PET Study data Sheet | 1 | - |
| PET Study Master List | 2 | 17/2/2020 |
| Investigator Brochure [18F] Fluoroestradiol | 5 | 26/12/2017 |
| PET Delegation Log Nepean Hospital | 1 | 27/5/2020 |
| PET Information Sheet and Consent Form | 5 | 27/5/2020 |
| PET Procedure Protocol | 1.0 | 9/5/2019 |
| PET SAE Form | 1.0 | 27/5/2020 |
| PET Safety Reporting Template for NBMLHD Sponsored Clinical Trials Therapeutic Goods | 1.0 | 27/5/2020 |
| PET Study Completion Form | 1.0 | - |

Approved Sites:

- **Nepean Hospital Nuclear Medicine Department**
- **Nepean Hospital Acute Gynaecology Service**
- **Sydney Adventist Hospital – 185 Fox Valley Road Wahroonga NSW**
- **OMNI Gynaecological Care, Ground Floor, Suite 2, 8 Northcote St, Naremburn NSW**

Yours Sincerely,



Clinical Professor Ian Seppelt
Chair, Human Research Ethics Committee
Nepean Blue Mountains LHD

Please quote project number and title in all correspondence